Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta

Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses. Part B: Part A, it is to Determine the Optimal Dose by Evaluating Two Capacity and Placebo Groups.

Chronic Liver Disease Clinical Trial

Official title:
LAENNEC (Human Placenta Hydrolysate) Stiffness of Chronic Liver Disease Patients to Evaluate the Safety and Effectiveness of Multi -Tube, Eye, Placebo, and Capacity Increase and Capacity Enlargement Clinical Trial to Assess the Safety and Effectiveness

See also
Status	Clinical Trial	Phase
Completed	`NCT03704792` - Validation of the Second Generation of the Controlled Attenuation Parameter (CAP) Using the MRI-PDFF as Reference	N/A
Terminated	`NCT02949375` - Trial to Examine the Effect of Two Doses of GRI-0621 in Patients With Chronic Liver Disease	Phase 2
Active, not recruiting	`NCT01205074` - ¹³C-Methacetin Breath Test (MBT) Methodology Study	Phase 2/Phase 3
Completed	`NCT00756171` - Colesevelam Versus Placebo in Cholestatic Pruritus	Phase 2/Phase 3
Completed	`NCT01195181` - Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.	Phase 4
Completed	`NCT05044663` - Liver and Splenic Stiffness in Predicting Esophageal Varices Needing Treatment in NASH Related Compensated Advanced Chronic Liver Disease.
Recruiting	`NCT04588077` - Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis	Phase 4
Recruiting	`NCT04802954` - Risk Stratification of Hepatocarcinogenesis Using a Deep Learning Based Clinical, Biological and Ultrasound Model in High-risk Patients	N/A
Recruiting	`NCT04622449` - Etiopathogenesis of Anemia in Chronic Liver Disease
Enrolling by invitation	`NCT05836246` - The Development of Quantitative Ultrasound Imaging Software Platform
Completed	`NCT03087344` - Postprandial Liver and Spleen Stiffness Measurements in the Noninvasive Diagnosis of Cirrhosis	N/A
Completed	`NCT04751045` - Comparison and Outcomes of Endoscopic Ultrasound Liver Biopsies Versus Percutaneous Liver Biopsies	N/A
Not yet recruiting	`NCT04526548` - A Diagnostic Study on Patients With Drug-induced Liver Injury
Withdrawn	`NCT02899325` - FDGal PET/CT to Detect Hepatocellular Carcinoma
Terminated	`NCT02530567` - Non-invasive Evaluation of Portal Pressure by MRI	N/A
Suspended	`NCT02650011` - Clinical Features and Natural History of Acute-on-Chronic Liver Failure in Korean Patients With Chronic Liver Disease
Completed	`NCT01851252` - MBT Versus HVPG in Identifying Responders to Portal Hypertension Therapy	Phase 1
Terminated	`NCT01756690` - Predicting Lung Injury From Transfusion in Patients With Liver Disease	N/A
Completed	`NCT01600105` - Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI)	Phase 4
Completed	`NCT01008293` - Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life	Phase 2/Phase 3

NCT number	NCT05532124
Study type	Interventional
Source	Green Cross Wellbeing
Contact	Yeongmin Kwon
Phone	+82-70-8892-7881
Email	ymkwon@gccorp.com
Status	Recruiting
Phase	Phase 2
Start date	June 1, 2021
Completion date	June 2023

Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses. Part B: Part A, it is to Determine the Optimal Dose by Evaluating Two Capacity and Placebo Groups.

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms